Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
This study is ongoing, but not recruiting participants.
Study NCT01100502 Information provided by Seattle Genetics, Inc.
First Received on April 6, 2010. Last Updated on April 19, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Physiological Effects of Drugs
Sponsors listed in this trial
Seattle Genetics, Inc.
Millennium Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers